WEBULL
WebtradeDownload

Iovance Biotherapeutics (IOVA) Could Be 43% Undervalued After Record Q2 Results

Simply Wall St · 22h ago

Iovance Biotherapeutics (IOVA) is back in focus after reporting record second quarter revenue near US$100 million with a 56% margin, along with wider access to its TIL platform and an expanding solid tumor pipeline.

The strong quarterly update has arrived alongside a sharp rebound in Iovance Biotherapeutics’ share price, with a 7-day share price return of 19.19% and a 90-day move of 162.15%. This has contributed to a year-to-date share price return of 306.75% and a 1-year total shareholder return of 400.00%. These figures contrast with a 5-year total shareholder return that is still down 58.93%, suggesting that recent momentum reflects shifting expectations around its TIL platform and pipeline news rather than a long, uninterrupted run higher.

Capture this kind of momentum early by scanning a curated set of 16 high quality undiscovered gems with fundamentals that can support strong market reactions to clinical and commercial updates.

The share price is now close to analyst targets, while one valuation model still implies a steep discount to fair value. Is the market being appropriately cautious on Iovance Biotherapeutics, or excessively skeptical?

Most Popular Narrative: 43.1% Undervalued

The most followed narrative on Iovance Biotherapeutics pegs fair value at $18 per share, compared to the recent close at $10.25, which frames the current rally as only a partial catch up rather than the end of the opportunity.

Today, the market capitalization is only around $2 billion, despite Iovance already having an FDA-approved product and guidance for hundreds of millions of dollars in revenue this year. If management executes as planned, I don't think the company should trade like an early-stage biotech anymore.

See why 20 investors see Iovance Biotherapeutics as 43% undervalued.

Result: Fair Value of $18 (UNDERVALUED)

Still, Iovance Biotherapeutics faces real pressure if Amtagvi uptake slows or key TIL trials disappoint, which could quickly cool sentiment around that undervaluation case.

Find out about the key risks to this Iovance Biotherapeutics narrative.

Another View on Iovance Biotherapeutics: Pricing vs Fair Ratio

Iovance Biotherapeutics may look inexpensive compared with a fair value of $35.65 from our DCF work, but the P/S ratio suggests a tougher story. The shares trade at 14.3x sales versus 12.3x for the US biotech group and a fair ratio of 8.4x. This raises the question of whether the current enthusiasm is already pricing in a lot of positive developments.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:IOVA P/S Ratio as at Sep 2026
NasdaqGM:IOVA P/S Ratio as at Sep 2026

Next Steps

Mixed sentiment around Iovance Biotherapeutics creates a real fork in the road, so move fast, pull up the full data set, and pressure test both the upside and the downside by weighing the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Iovance Biotherapeutics?

Do not stop with Iovance Biotherapeutics when there are plenty of other stocks that might suit your goals just as well or even better.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.